Domov › Kronična limfocitna levkemija › Pennsylvania
Klinične študije za Kronična limfocitna levkemija v Pennsylvania
22 študij za Kronična limfocitna levkemija išče udeležence na lokacijah v Pennsylvania.
Mesta v Pennsylvania
Uradno besedilo študije (angleško)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Geisinger Medical Center, Danville
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- in še 1
Vključevanje udeležencevFaza 3
Starost 65 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- in še 7
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- in še 4
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Penn State Milton S Hershey Medical Center, Hershey
- Thomas Jefferson University, Philadelphia
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- West Penn Hospital, Pittsburgh
- Cancer Care Associates of York, York
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Fox Chase Cancer Center, Philadelphia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall
- Cancer Care Associates Of York ( Site 0005), York
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07221500Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07061951A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Philadelphia
- Research Site, Pittsburgh
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07520006ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT07342478A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. jul. 2026 · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 12. jun. 2026 · NCT07271667A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Cancer Care Associates Of York, York
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 19. maj 2026 · NCT06588478A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University of Pennsylvania Hospital, Philadelphia
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University of Pennsylvania Hospital, Philadelphia
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876649Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Pennsylvania Oncology Hematolo /ID# 249637, Philadelphia
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 9. feb. 2026 · NCT04895436Two Step Haplo With Radiation Conditioning
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 30. okt. 2025 · NCT05031897Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18–79 · Vsi spoli · Posodobljeno 13. jan. 2025 · NCT05281809Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.